PBSS Free Online Symposium: Preclinical Models to Guide Therapeutic Development in Oncology

Day 1: December 08, 2020 – In Vivo Models and Case Studies with Targeted Therapeutics

Symposium Overview and Relevance to Contemporary Issues in Development of Therapeutic Agents for Oncology (Mark Merchant, Genentech)
Preclinical Mouse Models for Oncology and Immuno-oncology Applications (Maryland Franklin, Covance-Preclinical Oncology)
Preclinical Development of AMG 510, a First-in-human Covalent Inhibitor of KRASG12C for the Treatment of Advanced Solid Tumors (Karen Rex, Amgen)
Preclinical Investigation of NKTR-255, a Polymer Conjugated IL-15 with Potent NK cell Activation and anti-tumor activity in combination with tumor targeting antibodies (Willem Overwijk, Nektar Therapeutics)
Case Study: Bench to Bedside with Immune Stimulating Antibody Conjugates (ISAC) (Shelley Ackerman, Bolt Biotherapeutics)

Day 2: December 15, 2020- Models for CAR-T Therapy and Organoid Models

Symposium Overview and Relevance to Contemporary Issues in Development of Therapeutic Agents for Oncology (Mark Merchant, Genentech)
Advancing CAR T Cell Therapy for the Treatment of Solid Tumors (Saul Priceman, City of Hope)
The Utility of Preclinical Models in Development of CAR T (John Langowski, Kite Pharma)
Patient-Derived Oganoids in Cancer Research: Biobanking, Genome Engineering and Immune Cell Co-Cultures. (Yorick Post; formerly, Clevers Lab of Hubrecht Institute; currently Surrozen)
Use of Organoids in Cancer for Drug Screening, Biomarker Development and Personalized Patient Therapy. (Philippe Depeille; UCSF)
Patient-Derived and PDX-Derived Organoids for Oncology Drug Discovery (Dean Campbell, Crown Biosciences)